Ways And Means Drug Pricing Hearing Emphasizes Repetitive, Years-Old Questions
Executive Summary
There was little on specific legislative proposals and a lot of time discussing broad questions that Congress has been asking for years about drug pricing.
You may also be interested in...
House Drug Pricing Hearing Underscores Democrats' Challenges In Advancing Proposals
Republicans align against Medicare Part D price negotiation bill co-sponsored by Ways and Means Health Subcommittee Chair Lloyd Doggett, D-Tex.
Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
Value-Based Contracting Bill Aims For Bipartisan Political Support
Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.